Goldman Sachs
IMMX icon

Goldman Sachs’s Immix Biopharma IMMX Stock Holding History

Goldman Sachs’s Portfolio IMMX Stock Details IMMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.8M Buy
174,107
+78,703
+82% +$730K ﹤0.01% 4767
2026
Q1 		$869K Sell
95,404
-112,966
-54% -$830K ﹤0.01% 5189
2025
Q4 		$1.09M Buy
+208,370
New +$858K ﹤0.01% 5080

Other funds holding IMMX

Jupiter Topco
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Eventide Asset Management
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Goldman Sachs's IMMX Position: Q2 2026 in Review

Goldman Sachs increased its Immix Biopharma (IMMX) stake by 82% in Q2 2026, buying an estimated $730K and bringing the position to 174,107 shares worth $1.8M. The position accounts for ﹤0.01% of the portfolio, ranked #4767.

Goldman Sachs first reported a position in IMMX in Q4 2025 and has held it in 3 quarters since. 109 funds tracked by Wall St. Rank hold IMMX as of Q2 2026.

  • Goldman Sachs held 174,107 shares of Immix Biopharma worth $1.8M as of Q2 2026.
  • Goldman Sachs bought 78,703 Immix Biopharma shares in Q2 2026, an estimated $730K.
  • Immix Biopharma made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #4767 holding.
  • Goldman Sachs first reported a position in Immix Biopharma in Q4 2025 and has held it in 3 quarters since.
  • 109 funds tracked by Wall St. Rank held Immix Biopharma as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.